Fingolimod Tablet Shows ‘huge Promise’

New trial results presented at the American Academy of Neurology (AAN) congress and released today show the Novartis multiple sclerosis (MS) tablet FTY720 (fingolimod) to be potentially beneficial for people with relapsing-remitting MS. The Phase III results show that 80 to 83 per cent of patients taking the pill remained free of relapses during the one-year study compared to 69 per cent of those on interferon beta-1a, a current standard in treating MS relapses. Dr.

More: continued here

Filed under: Multiple Sclerosis on May 3rd, 2009